Lung Cancer Mutation Panel- EGFR PCR with ALK-D5F3 IHC

Patients with non-small cell lung cancer, particularly adenocarcinoma, are the primary candidates for this test as these types of cancers often have EGFR mutations or ALK rearrangements.

A positive result indicates the presence of either an EGFR mutation or an ALK rearrangement in the tumor sample. This suggests that the patient may benefit from therapies targeting these genetic changes.

A negative result means that the specific EGFR mutations and ALK rearrangements tested were not detected. However, it does not rule out the presence of other mutations or rearrangements in these or other genes.

While this test can identify specific mutations and rearrangements associated with certain types of lung cancer, it cannot predict how the disease will progress. Your doctor will use this information, along with other factors, to help estimate the likely course of your disease.

If an EGFR mutation or ALK rearrangement is detected, targeted therapies such as tyrosine kinase inhibitors can be used. These drugs are designed to specifically interfere with the function of the mutated or rearranged proteins, blocking their ability to promote cancer growth.

If no mutations or rearrangements are detected, traditional treatment options such as surgery, radiation, and chemotherapy may be recommended. Your doctor may also suggest other tests to look for different mutations.

The accuracy of this test is high, but it depends on the quality and type of the sample used. Inadequate sample or poor preservation of the tissue can affect the results.

Yes, in some cases, this test can be used to monitor your response to targeted therapies. Your doctor may recommend repeated testing during your treatment.

Since this test is usually performed on a tissue sample taken during a biopsy or surgery, the risks are associated with those procedures and not the test itself.

While some genetic tests can be performed on a blood sample, this test is usually done on a tissue sample from the tumor. However, liquid biopsy, a newer technique that looks for tumor DNA in the blood, may be used in certain situations.

Testing for both EGFR mutations and ALK rearrangements allows for a more comprehensive understanding of the genetic changes driving a patient's cancer. This information can help guide treatment decisions.

The frequency of testing will depend on your individual circumstances. Your healthcare provider will provide specific guidance based on your condition and response to treatment.

The turn-around time for this test is typically about a week, but it may vary depending on the lab.

While the test results are generally reliable, they do not provide a complete picture of all the genetic changes that may be present in a tumor. Other tests may be necessary to fully understand the genetics of your cancer.

No specific preparation is required for this test. It is important to discuss any concerns or questions you may have with your healthcare provider before the test.